$AZN (AstraZeneca PLC)

$AZN {{ '2016-01-05T14:46:09+0000' | timeago}} • Announcement

Under terms of licensing agreement, Millendo Therapeutics acquired global rights to develop and commercialize MLE4901. In exchange, $AZN will receive upfront payment and take an equity stake in Millendo, as well as development and commercial milestone payments. In addition, $AZN is eligible to receive royalties on net product sales.

$AGN {{ '2017-10-16T21:26:34+0000' | timeago}} • Announcement

Drugmaker $AGN gets an adverse effect from the U.S. District Court for the Eastern District of Texas. The judge invalidated Allergan's Restasis patent deal, which was signed with the Mohawk Tribe in the last month. Allergan plans to appeal the ruling. Restasis, a dry-eye treatment drug,  generated $1.5Bil of revenues for Allergan in 2016.

$MDT {{ '2017-10-16T20:09:05+0000' | timeago}} • Announcement

$MDT said its Medtronic Care Management Services (MCMS) business and American Well entered into a strategic partnership. Under the agreement, the businesses will work together to enable patient access to American Well's telemedicine services on MCMS' video-enabled platforms, and to allow bi-directional data flow between the two parties.

$LLY {{ '2017-10-16T19:27:03+0000' | timeago}} • Announcement

The BoD of $LLY declared a dividend for 4Q17 of $0.52 per share, payable on Dec. 8, 2017 to shareholders as of Nov. 15, 2017.

$AGN {{ '2017-10-12T22:44:22+0000' | timeago}} • Announcement

$AGN, which inked a controversial patent deal with Mohawk Tribe, reached a patent litigation settlement on its dry eye treatment drug Restasis with InnoPharma, a unit of $PFE. The litigation, which was filed in Sept. 2015 by Allergan, will be withdrawn and Allergan will grant license to InnoPharma to market Restasis from Feb. 2024 or earlier.

$LLY {{ '2017-10-12T14:50:24+0000' | timeago}} • Announcement

FDA grants priority review for $LLY's breast cancer drug Verzenio, which was approved by the agency on Sept. 28. 2017. Now, FDA will speed up the review and will take action within eight months.  On Oct. 10, 2017, Lilly announced that Verzenio failed in the Phase 3 study for treating advanced lung cancer.

$MCK {{ '2017-10-11T18:31:37+0000' | timeago}} • Announcement

Biologics, a $MCK Specialty Health oncology pharmacy services company, has been selected by $LLY to be in the limited distribution network for Verzenio (abemaciclib), $LLY's first oral oncolytic indicated for metastatic breast cancer. Verzenio obstructs growth of cancer cells by specifically blocking cyclin-dependent kinases, CDK4 and CDK6.

$AGN {{ '2017-10-10T18:02:39+0000' | timeago}} • Announcement

FDA accepts to review $AGN's New Drug Application seeking approval for ulipristal acetate, an investigational drug for the treatment of abnormal bleeding in women with uterine fibroids. Allergan expects the action date to occur in 1H18. According to the Agency for Healthcare Research and Quality (AHRQ), 26MM women in U.S. have got uterine fibroids.

$PG {{ '2017-10-10T16:14:25+0000' | timeago}} • Announcement

$PG's shareholders have voted to elect all 11 of its highly qualified Directors to its Board. Nelson Peltz of Trian was not elected to the Board. This is based on a preliminary vote count provided by its proxy solicitors following its 2017 Annual Meeting.

$LLY {{ '2017-10-10T13:44:54+0000' | timeago}} • Announcement

$LLY's advanced lung cancer treatment drug Verzenio flunks in meeting the end goal of overall survival among the 453 patients in the Phase 3 JUNIPER trial study. The most common adverse events experienced by these patients were diarrhea, fatigue, decreased appetite, and nausea. Last month, FDA approved Verzenio for the treatment of breast cancer.

$LLY {{ '2017-10-06T18:13:20+0000' | timeago}} • Announcement

The U.S. Patent and Trademark Office (PTO) ruled in favor of $LLY for its cancer drug Alimta. The review was initiated by Neptune Generics and Sandoz Inc and PTO concluded that claims of the Alimta vitamin regimen patent are valid. If the patent is upheld through all remaining challenges, Alimta would maintain U.S. exclusivity until May 2022.

$EBS {{ '2017-10-06T16:07:34+0000' | timeago}} • Announcement

$EBS completed its acquisition of Sanofi’s ACAM2000 (Smallpox Vaccine, Live) business, which includes ACAM2000, cGMP live viral manufacturing facility and office and warehouse space, both in Canton, Massachusetts, and a cGMP viral fill/finish facility in Rockville, Maryland.

$LLY {{ '2017-10-05T17:01:58+0000' | timeago}} • Announcement

$LLY announced that its breast cancer drug Verzenio (abemaciclib) will be available in U.S. by mid Oct.-2017. On Sept. 28, 2017, FDA approved Lilly's Verzenio.

$JNJ {{ '2017-10-05T13:58:49+0000' | timeago}} • Announcement

Animas Corp., a $JNJ Diabetes Care Companies, plans to discontinue the manufacturing and sale of Animas Vibe and OneTouch Ping insulin pumps, close operations and exit the insulin pump business. Animas has selected $MDT as its partner-of-choice to facilitate a seamless transition for patients, caregivers and healthcare providers.

$HRC {{ '2017-10-05T12:06:47+0000' | timeago}} • Announcement

Chairman of $HRC Board Rolf Classon will not stand for re-election to the BoD when his current term expires on March 6, 2018. The Board plans to appoint current independent director William Dempsey to this role if he is re-elected by shareholders. The company also elected Gary Ellis, retired CFO and SVP of $MDT, to its BoD, effective Oct 5, 2017.

$LLY {{ '2017-10-04T18:08:34+0000' | timeago}} • Announcement

Humalog Junior KwikPen, a prefilled and disposable half-unit insulin pen from $LLY, will be available now in U.S. for treating type 1 and type 2 diabetes. In June 2017, Humalog Junior KwikPen was approved by the FDA and it is expected to get the EU's approval later in 2017.

$GILD {{ '2017-10-04T14:22:07+0000' | timeago}} • Announcement

$GILD announced results from a Phase 3 study evaluating the efficacy of a fixed-dose combination of bictegravir (BIC), a novel investigational integrase strand transfer inhibitor (INSTI), and emtricitabine/tenofovir alafenamide (FTC/TAF), a dual-NRTI backbone in HIV-1-infected patients. The study found BIC/FTC/TAF to be superior to other regimens.

$GILD {{ '2017-10-04T13:59:54+0000' | timeago}} • Announcement

$GILD has also expanded its licensing agreements with Sun Pharmaceutical Industries Limited, Strides Shasun Limited, Mylan Laboratories Limited and SeQuent Scientific Limited to include BIC, and products incorporating the compound, for distribution in 116 developing countries.

$GILD {{ '2017-10-04T13:59:38+0000' | timeago}} • Announcement

$GILD announced a new licensing agreement with the Medicines Patent Pool (MPP) to expand access to bictegravir (BIC) upon regulatory approval in the US. BIC is used to treat HIV-1 infection. MPP can sub-license rights to BIC to companies in India, China and South Africa to manufacture therapies containing BIC for distribution in 116 countries.

$EBS {{ '2017-10-04T12:11:30+0000' | timeago}} • Announcement

$EBS has been awarded a contract valued at up to approximately $25MM by the U.S. Department of State to supply TROBIGARD auto-injector, a drug and device combination product for emergency use in the event of nerve agent or organophosphate poisoning.

$EBS {{ '2017-10-03T13:27:49+0000' | timeago}} • Announcement

Life sciences firm $EBS completed the acquisition of raxibacumab, an FDA-approved human monoclonal antibody for the treatment of inhalational anthrax, from $GSK. The company plans a $130MM contract with the Biomedical Advanced Research and Development Authority to supply the product to the US Strategic National Stockpile through November 2019.

Recent Transcripts

ENZ (Enzo Biochem Inc.)
Thursday, September 28 2017 - 12:30pm
MDT (Medtronic plc)
Tuesday, August 22 2017 - 12:00pm
ZGNX (Zogenix, Inc.)
Tuesday, August 8 2017 - 8:30pm
IONS (Ionis Pharmaceuticals, Inc.)
Tuesday, August 8 2017 - 3:30pm
EVHC (Envision Healthcare Holdings, Inc.)
Tuesday, August 8 2017 - 12:30pm
ARNA (Arena Pharmaceuticals Inc)
Monday, August 7 2017 - 8:30pm
CBM (Cambrex Corporation.)
Friday, August 4 2017 - 12:30pm
EBS (Emergent BioSolutions, Inc.)
Thursday, August 3 2017 - 9:00pm
IRWD (Ironwood Pharmaceuticals, Inc.)
Thursday, August 3 2017 - 8:30pm
AGN (Allergan plc)
Thursday, August 3 2017 - 12:30pm
FVE (Five Star Quality Care Inc.)
Wednesday, August 2 2017 - 2:00pm
DVA (DaVita HealthCare Partners Inc.)
Tuesday, August 1 2017 - 9:00pm
KTWO (K2M Group Holdings, Inc.)
Tuesday, August 1 2017 - 9:00pm
ILMN (Illumina Inc.)
Tuesday, August 1 2017 - 8:30pm
FMS (Fresenius Medical Care AG & Co. KGAA)
Tuesday, August 1 2017 - 1:30pm
ABBV (AbbVie Inc.)
Friday, July 28 2017 - 1:00pm
BMY (Bristol-Myers Squibb Company)
Thursday, July 27 2017 - 2:30pm
RDY (Dr. Reddy's Laboratories Ltd.)
Thursday, July 27 2017 - 1:00pm
AZN (AstraZeneca PLC)
Thursday, July 27 2017 - 12:30pm
ALKS (Alkermes plc)
Thursday, July 27 2017 - 12:30pm

AlphaGraphics you may like